Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

GlobeNewswireNov 27 20:00

Perspective Therapeutics Downgraded to Neutral From Buy at BofA

Yahoo FinanceNov 26 19:45

Perspective Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesNov 25 23:55 · Ratings

BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6

Futu NewsNov 25 23:33 · Ratings

RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $16

Futu NewsNov 25 20:31 · Ratings

RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk

MT NewswiresNov 25 20:07 · Ratings